An interventional study of Ringer's Lactated in Placenta Accreta Spectrum, sponsored by Maternal and Child Health Hospital of Foshan. Withdrawn at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-04-25.
Sponsored by Maternal and Child Health Hospital of Foshan · Not applicable, Interventional, and Treatment
Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion. Clinical evidences have confirmed that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. Normal saline is the solution recommended for red cell washing, administration and salvage. However, there is growing concern that normal saline is more toxic than balanced, buffered crystalloids such as Lactated Ringer's and Plasma-Lyte. The purpose of this study is to evaluate the blood components using of Ringer's Lactated by a prospective, single-center, open, and single-arm clinical trial.
147 studies on the registry are indexed under Placenta Accreta; 39 are open to participants now.
Browse Placenta Accreta studies →Maternal and Child Health Hospital of Foshan is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Using of Ringer's Lactated
Other: Ringer's Lactated
Using of Ringer's Lactated In Autologous Blood Cell Transfusion
Change in hematological parameters
erythrocytes (/µL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Change in hematological parameters
hemoglobin (g/dL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Change in hematological parameters
Mean corpuscular volume (fL)
Time frame: Baseline (Day 1), until 2 days after autotransfusion
Plan to share: Undecided
No publications or documents are linked to this record.
This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maternal and Child Health Hospital of Foshan